Inhibition of prostate cancer growth by estramustine and etoposide

Kenneth Pienta, B. G. Redman, M. Hussain, P. S. Esper, L. E. Flaherty

Research output: Contribution to journalArticle


Background. Metastatic prostate cancer that is refractory to hormone therapy remains an incurable disease without effective therapy. The authors used the nuclear matrix, the RNA-protein network of the nucleus that plays an important role in DNA replication and gene expression, as a target for cancer chemotherapy. In preclinical models, estramustine and etoposide appeared to interact to inhibit the growth of the hormone-refractory prostate cancer cells. Methods. These agents were tested in a Phase II clinical trial of patients with metastatic hormone-refractory prostate cancer. Estramustine, 15 mg/kg/day, and etoposide, 50 mg/M2/day, were administered orally in divided doses for 21 days every 28 days. Therapy continued until evidence of disease progression. Results. Fifty-two patients were enrolled in this trial and had a minimum of 40 weeks follow-up. In 20 patients with measurable soft tissue disease, 3 patients demonstrated a complete response (15%) and 6 patients had a partial response (30%) for more than 2 months. Of 32 patients with disease limited to bone, 8 (25%) demonstrated improvement and 12 (38%) demonstrated stability in their bone scans. Overall, 13 men (25%) demonstrated a decrease of at least 75%, and 28 men (54%) demonstrated at least a 50% decrease in their pretreatment prostate specific antigen levels. Conclusions. The combination of estramustine and etoposide may be an active oral regimen in hormone-refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)1920-1926
Number of pages7
Issue number7 SUPPL.
Publication statusPublished - 1995
Externally publishedYes



  • adenocarcinoma
  • Dunning
  • estramustine
  • etoposide
  • hormone- refractory
  • prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pienta, K., Redman, B. G., Hussain, M., Esper, P. S., & Flaherty, L. E. (1995). Inhibition of prostate cancer growth by estramustine and etoposide. Cancer, 75(7 SUPPL.), 1920-1926.